Prolor hired Jeffreys to purchase worth $ 800 million
hormone, which produces BioMed indexes beginning versions: Pfizer, nobortis, ??????????'?????? and nature. The last Chairman, Philip Frost, holds 19.8% stake in prolor. Jeffreys led to the call-up of prolor on NASDAQ last year
other Israeli BioMed Corp. is in preliminary negotiations for sale. Property "was informed that Chairman of prolor biotech company headed by nature Philip Frost hired u.s. Investment Bank Jeffreys, to examine various strategies and options, including the sale of the company, as well as formulating an analysis of each of the three become products.
Read more lectures at HR seminar:
Searching medicine organize the future
The real heroes of the high-tech industry: leading BioMed indexes beginning companies
Another unknown property "that four companies contemplating the purchase of prolor-Pfizer, Novartis, ??????????'?????? and nature, and that the price to which the shareholders of the company is aiming at up to 800 million dollars, although the company is worth $ 322 million. However, due to its primary product--the vast potential for growth hormone. Recently it was reported that nature was for purchasing contacts protalix however these were discontinued.
In may 2012, the Bank has led the recruitment of Jeffreys 37 million dollars on NASDAQ, lprolor and costs 5 dollars per share, the price at which the stock trades today. Reference ??'???? now was made after the company has received inquiries from major companies who have expressed interest in various collaborations with respect to its products and commercial agreements with prolor.
3 billion market
Adult growth hormone market rolls about 1 billion dollars worldwide, and the treatment of children rolling ??2 billion. While children with hormone deficiency are treated to high, old symptoms in adults causes scarcity, such as increased risk of heart disease, increased levels of fat and bone hbtani, and the company hopes to get approval for the product ??2015.
Frost holds a 19.8% interest in prolor, and Dr. Jane hsiao, former Vice Chairman and Vice Chairman of the aioox-controlled company opko Frost that is controlled by the Frost, which holds about 3.4%. Frost holds a 1.5 percent stake in another nature worth $ 578 million.
Prolor is using the patented CTP technology, especially the development of long-range versions of existing drugs. The company's flagship product is an advanced clinical stages is a long-range version of human growth hormone. The company also is developing long-range versions of factors for bamopilia, vbashmant, vglokgon for diabetes, all of which are in clinical development phase violation.
The main asset of both development and commercialization rights to prolor that received from the University of Washington in St. Louis ?????"? on the CTP technology, which tie short protein (peptide) proteins in blood cultures, drug them and extends the duration of their activity without increasing the damage they cause to the body and reduce their biological activity.
http://www.calcalist.co.il/markets/articles/0,7340,L-3599818,00.html